GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF 2024). The event will take place from October 12-16, 2024, in Athens, Greece.
The company's abstract has been accepted for a poster presentation titled "Involvement of Type 1 Invariant Natural Killer T Cells in Driving Lung Fibrosis." Dr. Vipin Kumar Chaturvedi, GRI Bio's Chief Scientific Officer, will present the poster (Number PP 184) on Tuesday, October 15, 2024, from 3:30 PM to 5:00 PM EEST.
This presentation highlights GRI Bio's ongoing research in the field of lung fibrosis and demonstrates the company's commitment to advancing its innovative pipeline of NKT cell modulators for treating various diseases.
GRI Bio (NASDAQ: GRI), un'azienda biotecnologica focalizzata nello sviluppo di modulatori delle cellule Natural Killer T (NKT) per malattie infiammatorie, fibrotiche e autoimmuni, ha annunciato la sua partecipazione al 22° Colloquio Internazionale sulla Fibrosi Polmonare e delle Vie Aeree (ICLAF 2024). L'evento si terrà dal 12 al 16 ottobre 2024, ad Atene, Grecia.
Il riassunto dell'azienda è stato accettato per una presentazione poster intitolata "Coinvolgimento delle cellule Natural Killer T invariant di Tipo 1 nella guida della fibrosi polmonare." Il Dr. Vipin Kumar Chaturvedi, Chief Scientific Officer di GRI Bio, presenterà il poster (Numero PP 184) martedì 15 ottobre 2024, dalle 15:30 alle 17:00 EEST.
Questa presentazione evidenzia la ricerca in corso di GRI Bio nel campo della fibrosi polmonare e dimostra l'impegno dell'azienda a promuovere il suo innovativo pipeline di modulatori delle cellule NKT per il trattamento di diverse malattie.
GRI Bio (NASDAQ: GRI), una empresa de biotecnología enfocada en el desarrollo de moduladores de células Natural Killer T (NKT) para enfermedades inflamatorias, fibróticas y autoinmunes, ha anunciado su participación en el 22º Coloquio Internacional sobre Fibrosis Pulmonar y de las Vías Respiratorias (ICLAF 2024). El evento se llevará a cabo del 12 al 16 de octubre de 2024, en Atenas, Grecia.
El resumen de la empresa ha sido aceptado para una presentación de póster titulada "Participación de las células Natural Killer T invariantes de Tipo 1 en la conducción de la fibrosis pulmonar." El Dr. Vipin Kumar Chaturvedi, Director Científico de GRI Bio, presentará el póster (Número PP 184) el martes 15 de octubre de 2024, de 15:30 a 17:00 EEST.
Esta presentación resalta la investigación continua de GRI Bio en el campo de la fibrosis pulmonar y demuestra el compromiso de la empresa con el avance de su innovadora cartera de moduladores de células NKT para el tratamiento de diversas enfermedades.
GRI Bio (NASDAQ: GRI)는 염증성, 섬유성 및 자가면역 질환을 위한 자연 살해 T 세포(NKT) 조절제 개발에 집중하는 생명공학 회사로서, 제22차 국제 폐 및 기도 섬유증 콜로키움 (ICLAF 2024)에 참여한다고 발표했습니다. 이 행사는 2024년 10월 12일부터 16일까지 그리스 아테네에서 개최됩니다.
회사의 초록은 "폐 섬유증을 유도하는 제1형 불변 자연 살해 T 세포의 관여"라는 제목의 포스터 발표로 수락되었습니다. GRI Bio의 최고 과학 책임자인 Vipin Kumar Chaturvedi 박사가 2024년 10월 15일 화요일, 오후 3시 30분부터 5시 EEST까지 포스터 (번호 PP 184)를 발표할 예정입니다.
이번 발표는 GRI Bio의 폐 섬유증 분야에서의 지속적인 연구를 강조하며, 다양한 질환 치료를 위한 NKT 세포 조절제의 혁신적인 파이프라인 발전에 대한 회사의 의지를 보여줍니다.
GRI Bio (NASDAQ: GRI), une entreprise de biotechnologie axée sur le développement de modulateurs de cellules Natural Killer T (NKT) pour les maladies inflammatoires, fibreuses et auto-immunes, a annoncé sa participation au 22e Colloque International sur la Fibrose Pulmonaire et des Voies Respiratoires (ICLAF 2024). L'événement se déroulera du 12 au 16 octobre 2024 à Athènes, en Grèce.
Le résumé de l'entreprise a été accepté pour une présentation de poster intitulée "Implication des cellules Natural Killer T invariantes de type 1 dans la progression de la fibrose pulmonaire." Le Dr Vipin Kumar Chaturvedi, Directeur Scientifique de GRI Bio, présentera le poster (Numéro PP 184) le mardi 15 octobre 2024, de 15h30 à 17h EEST.
Cette présentation met en lumière les recherches en cours de GRI Bio dans le domaine de la fibrose pulmonaire et démontre l'engagement de l'entreprise à faire avancer son portefeuille innovant de modulateurs de cellules NKT pour traiter diverses maladies.
GRI Bio (NASDAQ: GRI), ein Biotechnologieunternehmen, das sich auf die Entwicklung von Modulatoren von Natural Killer T (NKT) Zellen für entzündliche, fibrotische und autoimmune Erkrankungen konzentriert, hat seine Teilnahme am 22. Internationalen Kolloquium über Lungen- und Atemwegsfibrose (ICLAF 2024) angekündigt. Die Veranstaltung findet vom 12. bis 16. Oktober 2024 in Athen, Griechenland, statt.
Die Zusammenfassung des Unternehmens wurde für eine Posterpräsentation mit dem Titel "Beteiligung von Typ 1 invarianten Natural Killer T Zellen an der Förderung von Lungenfibrose" akzeptiert. Dr. Vipin Kumar Chaturvedi, Chief Scientific Officer von GRI Bio, wird das Poster (Nummer PP 184) am Dienstag, dem 15. Oktober 2024, von 15:30 bis 17:00 EEST präsentieren.
Diese Präsentation hebt die laufende Forschung von GRI Bio im Bereich der Lungenfibrose hervor und zeigt das Engagement des Unternehmens, seine innovative Pipeline von NKT-Zellmodulatoren zur Behandlung verschiedener Erkrankungen voranzutreiben.
- None.
- None.
LA JOLLA, CA, Oct. 07, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for a poster presentation at the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF 2024) being held October 12-16, 2024 in Athens, Greece.
Details of the poster presentation are as follows:
Title: Involvement of Type 1 Invariant Natural Killer T Cells in Driving Lung Fibrosis
Presenter: Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio
Poster Number: PP 184
Date and Time: Tuesday, October 15, 2024, 3:30 PM – 5:00 PM EEST
For more information about the event, please visit the conference website here.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
FAQ
What is GRI Bio presenting at ICLAF 2024?
When and where is GRI Bio's poster presentation at ICLAF 2024?
Who is presenting GRI Bio's research at ICLAF 2024?
What is the focus of GRI Bio's research presented at ICLAF 2024?
What is GRI Bio's stock symbol?
